TVTX — Travere Therapeutics, Inc.

Summary of Travere Therapeutics, Inc. Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total U.S. Net Product Sales: $124.5 million for Q1 2026, with FILSPARI sales contributing approximately $105.2 million, an 88% year-over-year increase.
• Total Revenue: $127.2 million, including $19.3 million from Thiola and $2.7 million in licensing revenue.
• Net Loss: $37.1 million, or $0.40 per basic share, improved from a loss of $41.2 million, or $0.47 per share, in Q1 2025.
• Non-GAAP Adjusted Net Income: $4.1 million, or $0.05 per share, compared to a loss of $16.9 million, or $0.19 per share, in the prior year.
• Cash Position: Approximately $352 million in cash, cash equivalents, and marketable securities as of March 31, 2026.

2. Strategic Updates and Business Highlights

• FDA Approval: Achieved full FDA approval for FILSPARI in FSGS, marking it as the first approved treatment for this condition.
• Patient Population: Over 100,000 patients in the U.S. are estimated to be eligible for FILSPARI across IgA nephropathy and FSGS, representing a potential $3 billion peak sales opportunity.
• Commercial Performance: Record demand for FILSPARI in IgA nephropathy with 993 new patient start forms in Q1, indicating strong market penetration.
• Pipeline Development: Dosed the first patient in the Phase III HARMONY study for pegtibatinase, with top-line results expected in 2027.

3. Forward Guidance and Outlook

• Revenue Growth: Anticipated continued strong demand for FILSPARI in both IgA nephropathy and FSGS, with expectations for sustained revenue growth.
• Investment Focus: Plans to invest in the commercialization of FILSPARI and the advancement of the HARMONY study for pegtibatinase.
• Market Positioning: Confident in the ability to leverage existing resources and a strong commercial team to drive growth.

4. Bad News, Challenges, or Points of Concern

• Operating Expenses: Increased R&D expenses ($57.1 million) and SG&A expenses ($80.3 million) due to investments in FILSPARI’s launch and pipeline development.
• Competitive Landscape: Potential pressure from competitors in the IgA nephropathy space, particularly with new entrants, though management believes FILSPARI's unique positioning mitigates this risk.
• Payer Dynamics: Need for ongoing education among physicians regarding FILSPARI’s eligibility criteria, particularly concerning nephrotic syndrome, which could impact adoption rates.

5. Notable Q&A Insights

• FSGS Launch Expectations: Management expressed confidence in a faster uptake for FILSPARI in FSGS compared to IgA nephropathy due to high unmet need and existing physician familiarity with the product.
• Payer Approval Rates: Early indications suggest higher first-pass payer approval rates for FSGS compared to IgA nephropathy, enhancing confidence in market penetration.
• Physician Education: Ongoing efforts to clarify the distinction between active nephrotic syndrome and nephrotic-range proteinuria to facilitate prescribing.
• Market Dynamics: Management emphasized that the growth in the IgA nephropathy market is driven more by overall market expansion rather than direct competition, positioning FILSPARI favorably.

Overall, Travere Therapeutics demonstrated strong financial performance and strategic progress in Q1 2026, with a positive outlook for continued growth despite some challenges in the competitive landscape and the need for ongoing physician education.